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ABSTRACT OF THE DISSERTATION
TECHNOBIOLOGY PARADIGM IN NANOMEDICINE:
TREATING CANCER WITH MAGNETOELECTRIC NANOPARTICLES
by
Emmanuel Stimphil
Florida International University, 2017
Miami, Florida
Professor Sakhrat Khizroev, Major Professor
Today, cancer is the world’s deadliest disease. Despite significant progress to find a cure,
especially over the last decade, with immunotherapy rapidly becoming the state of the art,
major open questions remain. Each successful therapy is not only limited to a few cancers
but also has relatively low specificity to target cancer cells; although cancer cells can
indeed be eradicated, many normal cells are sacrificed as collateral damage. To fill this
gap, we have developed a class of multiferroic nanostructures known as magnetoelectric
nanoparticles (MENs) that can be used to enable externally controlled high-specificity
targeted delivery and release of therapeutic drugs on demand. First, the underlying
physics of MENs was studied, as it relates to different externally applied sequences of a.c
and d.c. magnetic fields to facilitate (i) high-specificity targeting driven by a physical
force rather than antibody matching, (ii) a delivery mechanism that enhances cellular
uptake (via nanoelectroporation) of therapeutic drugs across the cellular membrane of
cancer cells only, and (iii) an externally controlled mechanism that releases the
therapeutic drug on-demand. Secondly, the application of MENs as a nuclear magnetic
resonance (NMR) nanoprobe was explored. The intrinsically coupled ferromagnetic and
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ferroelectric phases allowes the nanoparticle to be used as sensitive nanoprobe detectors
of biological cells; based on the knowledge that the cellular membrane is an electrically
charged medium which creates an ideal environment for MENs to distinguish between
cancer and normal cells. Lastly, through in-vivo and in-vitro studies, MENs were used as
drug delivery vehicle capable of crossing the blood brain barrier (BBB) and delivering
recently discovered MIA690 peptide drug (via nanoelectroporation) to glioblastoma
multiforme (GBM) brain cancer cells. Glioblastomas are tumors that arise from
astrocytes in the brain; that are highly malignant and reproduces quickly due to their large
network of blood vessels. In the following study, we report the binding efficacy of
MIA690 to magnetoelecric nanoparticles as well as present an unprecedented targeted
and on-demand release to glioblastoma cells through special sequences of a.c. and d.c.
magnetic fields. The potential therapeutic and diagnostic impact of MENs for future
medicine is beyond the scope of this study, as MENs can be used to treat any type of
cancer.
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CHAPTER I: INTRODUCTION
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Motivation
The cardiovascular system permits the transportation of drugs to almost every cell in the
body; however, transporting a drug specifically into a tumor cell past the cellular
membrane without affecting surrounding normal cells remains a key challenge in
addressing the cure for cancer. Targeted therapies have emerged as a promising approach
in cancer treatment, the development of monoclonal antibodies (mAbs) to target overly
expressed specific epitopes throughout the body has become a standard practice (1, 2).
Alternatively, on-going research to address this fundamental challenge in cancer
treatment by way of nanoparticles is being designed to be used as drug delivery vehicles.
Current nanoparticle based drug delivery systems conjugated with mAbs indeed display
novel properties; due to their unique sizes and shapes they help steer the drug loaded
nanoparticles to specific targets while meeting a wide range of requirements for
overcoming biological barriers throughout the circulatory system. However, they are also
extremely inefficient due to their dependence on the cellular microenvironment and the
cells’ physiological condition for triggering drug delivery; Nanoparticles have been
functionalized for triggered drug release through various means such as external applied
temperatures(3, 4), ultrasound(5), intracellular pH(6-8), and magnetic fields(9, 10).
Nevertheless, these approaches are inadequate and inefficient. To address this problem,
we have developed a new class of multiferroic nanostructures known as magnetoelectric
nanoparticles (MENs). These nanoparticles allow an external magnetic field the ability to
control an intrinsic electric field on the surface of the nanoparticles which in turn controls
the molecular mechanism of the ionically-bonds therapeutic drug onto the nanoparticle as
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well as the underline physical-interaction between the drug-loaded nanoparticle and
surround cells. In this dissertation, the following specific aims will be addressed.

Specific Aim 1: Explore the underlying physics of magneto-electric nanoparticles to
understand how they’re able to address the fundamental challenges we are currently
facing in cancer treatment. We will study the following MENs properties: (a) the
targeting mechanism driven by a physical force rather than antibody matching, (b) the
delivery mechanism that enhances the cellular uptake of therapeutics to cancer cells only;
without affecting surrounding normal cells, and (c) the externally controlled mechanism
that releases the therapeutic load on-demand (Chapter II).

Specific Aim 2: The presence of MENs’ intrinsic magnetoelectric (ME) effect allow the
conversion of electric energy to magnetic energy and vise-a-versa. We will explore an
application in which MENs are used as nuclear magnetic resonance (NMR) sensitive
nanoprobes. Based on the cancer cell type and corresponding nanoparticle-cell
association, MENs will be used to identify biological cells. Currently, the signal magnetic
resonance imaging (MRI) and magnetic particle imaging (MPI), is mainly dependent on
the magnetic saturation and the density of the current contrasting agents. Adding the
dimensionality of the intrinsic electric properties of the microenvironment and equating
those properties with MENs’ (ME) effect will establish a characteristic signature of
individual cells depending on the cancer cell type and progression stage (Chapter III).
Specific Aim 3: Through in-vitro and in-vivo studies the abilities of MENs to cross the
blood

brain

barrier

(BBB)

and

provide
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high-specificity

drug

delivery

via

nanoelectroporation to treat human glioblastoma multiforme (GBM) brain cancer cells,
respectively, will be explored (Chapter IV).

Background
For decades, researchers have attempted to develop means for targeting and delivery of
therapeutic drugs to diseases with high efficiency, precision, and solubility to maximize
the bioavailability of the therapeutic drug. More recently, several nanomaterals with
various compositions and biological properties have been designed to carry therapeutic
drugs to targeted sites. These nanomaterials show promising results of delivering
therapeutics to the targeted site with more precision when compared to conventional drug
delivery methods. This allows for minimizing the drug dose levels in treating the illness,
which in turn reduces the side effect caused from toxicity to surrounding normal cells.
Aside from the targeting and delivering applications, nanomaterials have been widely
used in cell imaging, diagnostics, and detection to mention a few. The more widely used
nanomaterals for these applications have been gold nanoparticles (AuNPs), iron oxide
(Fe3O4) nanoparticles, and more recently magneto-electric nanoparticles. An overview of
the commonly used nanomaterials and their applications will be discussed in the
following sections.
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Gold Nanoparticles (AuNPs)
Gold nanoparticles (AuNPs) are one of the most widely used nanomaterial in the field of
nanomedicine. The drug release mechanisms of AuNPs conjugated with mAb to
adequately deliver the drug to a cell have been shown to rely highly on a physiological
stimulus; i.e., internal stimuli such as the cells’ pH level and intracellular enzymes; and
external stimuli such as light and temperature (11-13). AuNPs have also been used in
photothermal therapy to eradicate cancer cells; Due to the strong electric field at the
surface of the noble metal, when the nanoparticles accumulate near the cancer site and
irradiated with an external laser source (14, 15), the absorption and scattering of the
electromagnetic radiation producing enough heat to eradicate the surrounding tumor
cells. Due to the light emission and scattering properties of AuNPs, they are also used as
nanoprobes for locating and imaging tumors, the emitted radiation is captured using light
scattering and surface plasmon resonant absorption spectroscope to produce an image of
the tumor site(16). An illustration of AuNPs for delivering therapeutic drugs and for
imaging is shown in Fig. 1.1a and b, respectively.
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Figure 1.1 Gold Nanoparticles (AuNPs) for delivering therapeutic agents and imaging
cancerous cells. A) AuNPs for delivering the therapeutic agents. a) bare-AuNPs, b)
AuNPs loaded with therapeutic agent (proteins/DNA/RNA/drugs), c) encapsulation of
AuNPs loaded with therapeutic agents, and d) release of therapeutic agents by the
physiological (pH and temperature) and external stimulatons (lights).B) AuNPs for
imaging cancerous cells. a) cancer cell surface with biomarkers, b) AuNPs, tagged with
anti-biomarkers, c) accumulations of biomarker tagged-AuNPs on cancer cell surface,
and d) a surface plasmon resonant absorption spectroscope image showing only cancer
cells through AuNPs accumulation (Guduru et al).

The advantages of AuNPs are: (i) biocompatibility due to its’ inert and non-toxic nature,
(ii) simplicity to fabricate and functionalization the surface of the nanoparticle, and (iii)
physical properties of light emission and scattering which enables them to be nanoprobes
for cancer cell imaging. The disadvantages of AuNPs are: (i) Inefficient drug release
mechanism due to the dependence on the microenvironment conditions, (ii) Inability to
image deep-tissue carcinoma due to the limitation of visible light penetration of a few
hundred microns and (iii) targeted ability is completely driven by antibody matching
which limits the application to those specific biomarkers.
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Iron oxide nanoparticles
More recently the use of iron oxide nanoparticles, especially Fe3O4 (magnetite) has
become extremely popular due to their biocompatibility and their non-toxic nature. The
development of various medical applications has been possible due to their unique
properties. The ability of these nanoparticles to react to a magnetic force has been utilized
in applications such as drug delivery, cell isolation and labeling, tissue repair, and
hyperthermia. In the following sections an overview of these applications will be
discussed.

Drug delivery
Like AuNPs, Fe3O4 nanoparticles which are magnetic nanoparticles (MNPs) can be used
as drug delivery vehicles tailored to carry a wide range of therapeutics (drugs,
DNA/RNA, and proteins) to the targeted site. Unlike AuNPs, MNPs non-zero magnetic
moment allows the nanoparticle can be guided to the tumor site using an external
magnetic field gradient, which eliminates the need to use mAbs for targeting. To avoid
these nanoparticles from being recognized by the reticuloendothelial clearance system the
MNPs’ surface is modified with a hydrophilic molecule known as poly ethylene glycol
(PEG).

Cell labeling and Cell Isolation
Cell labeling using MNPs begin by first conjugating the MNPs with mAbs to target
specific cell types throughout the circulatory system. Once the antigen-antibody reaction
or receptor is identified, the tagged MNPs is uptaken by the cell through mediated
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endocytosis or phagocytosis. Due to the magnetic properties of the nanoparticle we can
use magnetic resonance imaging (MRI) and magnetic particle imaging (MPI) to detect
and track the labeled cells. Due to the high saturation magnetization MPI can directly
detect the signal from these nanoparticles to produce a 3D location and concentration of
the nanoparticles within the circulatory system. The iron oxide nanoparticles are cleared
naturally by the body through the mononuclear phagocyte system, which is then broken
down in the liver and stored as iron to produce hemoglobin. The process of cell isolation
from a biological fluid can be accomplished through incubating the tagged MNPs with
cells in a Petri dish, once the MNPs attaches to the desired cells, wash away the excess
cell labeled MNPs on a magnetic rack which in turn isolates the desired cells.

To summarize, the main advantages of using magnetic nanoparticles over non-magnetic
nanoparticles are: (i) MNPs are able to be used as targeting vehicles for cancer cell, (ii)
MNPs have the ability to be a contrast agent for MRI and MPI imaging, (iii) MNPs are
able to be guided to any region in the body using an external magnetic field, and (iv) the
temperatures of MNPs can be increased using high frequency magnetic fields to release
therapeutic drugs off the surface of the nanoparticle as well as be used for thermal
therapy to eradicate cancer cells.
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Multiferroic Nanoparticles
Multiferroics are materials that exhibit more than one of the ferroic order parameters such
as ferromagnetism, ferroelectric, and ferroelasticity in the same phase. In the case of
nanoparticles, we will focus on a multiferroic known as magnet-electric nanoparticle
which demonstrates both ferroelectric and ferromagnetism parameters. The magnetic to
electric energy conversion and vise-versa exploits the properties of two different phases,
from two different materials simultaneously. The ferromagnetic material has a
magnetostrictive property that connects to the piezoelectric property of the ferroelectric
material. Thus, when an external magnetic field (∆H) is applied, magnetostrictive stress
is applied to the magnetic material causing a dipole ferromagnetic phase transfer to the
ferroelectric phase causing a polarization (∆P) to the associated electric field (∆E).
Performance of these materials is based on the phase transfer efficiency, known as
magneto-electric coefficient (a = ∆P/∆H) or magneto-electric voltage coefficient (aE =
∆E/∆H). The magneto-electric coefficients of commonly used composites are shown in
Table.1.

Table 1: Magnetoelectric coefficients of two-phase systems. (Note: BaTiO3, Pb(Zr,Ti)O3
(PZT) are ferroelectric materials; and TbxDy1-xFe2 (Terfenol-D), ferrites, and manganite
are ferromagnetic materials. ME coefficient measured in mv cm-1 Oe-1)
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The particulate composite morphology of these two-phase systems allows for better
control of the magneto-electric effect due to the shape effects. The spherical shape of the
composite provides a better transfer of magnetostrictive stress from the ferromagnetic
phase to the ferroelectric phase. These two-phase systems have been the gold-standard
for decades in many fields involving electronics, but more recently our group has
implemented these two-phase systems to biomedical applications coining the term
“Technobiology”.

Experimental Background
Magnetic-Nanoprobe Bio-sensing
Early detection of cancer is key to creating a cancer-free world and helping those living
with cancer. Researchers have proven that early stage treatment of premalignant
abnormal cells is more effective and increases the rate of a successful treatment and
extended life. However, traditional techniques have proven to be inefficient in cost,
performance, and development. In the past, the screening of cancer has led to false
positive and false negative results and consequently extremely invasive procedures have
been performed. As a result, more recently there has been increased interest in magnetic
nanoparticles bio sensing. Due to a new dimensionality provided by the presence of
externally-controlled magnetic moments, magnetic nanoparticle bio sensing promises to
enable high-specificity screening and fast diagnostics of cancer cells. Currently, the main
challenge is coupling the magnetic nanoparticle to intrinsic information at the cellular or
intracellular level with sufficiently high efficacy to process the information with current
magnetic detection systems (17-19). In chapter 3 of this dissertation, using a two-phase
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nanoparticle composite we will investigate the coupling of magneto-electric nanoparticles
to the electric signature of cells. The signatures obtained from each cell will correspond
to a specific cell type and cancer progression stages bringing us one step close to rapid
identification and early detection of cancer cells.

Multiferroic Nanostructure Drug Deliver
Multiferroic nanostructures exist when the crystal structures of two or more primary
ferroic materials’ properties are united in the same phase. In the case of our coreshell
magneto-electric nanoparticles (MENs), composed of a spinel-core cobalt iron oxide
(CoFe2O4) and perovskite-shell barium titanate (BaTiO3), at the nanoscale creates a
nanotechnology capable of being externally controlled to deliver therapeutic drugs to
cancer cells on demand with record-high specificity(20). Furthermore, such control can
be physically separated via application of d.c. and a.c. magnetic fields, respectively. The
control is achieved because, unlike traditional purely magnetic nanoparticles, MENs
display a non-zero magnetoelectric (ME) effect due to their strongly coupled
magnetostrictive and piezoelectric properties. Because of the ME effect, MENs provide a
unique way to use external magnetic fields to control intrinsic electric fields which
underlie the chemical bonds between the nanoparticle and the loaded drug as well as the
interaction between the drug-loaded nanoparticle and the cellular microenvironment. In
chapter 4 we will investigate how MENs are able to deliver therapeutic peptides past the
blood brain barrier (BBB) to glioblastoma multiforme (GBM) brian cancer.
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Conclusion
The discovery of these exceptional capabilities of magneto-electric nanoparticles bridges
the gap between nanotechnology and biology unprecedentedly. Throughout this
dissertation, we will demonstrate that the intrinsic quantum mechanically coupled
ferromagnetic and ferroelectric properties within these nanoparticles can be used for
high-specificity therapeutic drug delivery. Furthermore, the intrinsic coupling between
the magnetostrictive and piezoelectric phases allow MENs to be used as nuclear magnetic
resonance sensitive nanoprobes for rapid cancer screening. In parallel, we will explore
the underlying mechanism that defines the cell-nanoparticle interaction; which will lead
to the optimization of these nanoparticles to be tailored to any type of cancer and/or
normal cell.
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CHAPTER II: PHYSICS CONSIDERATION IN TARGETED ANTICANCER DRUG
DELIVERY BY MAGNETOELECTRIC NANOPARTICLES

13

Introduction
Adequately high specificity to target cancer cells while sparing normal cells remains one
of the greatest challenges in cancer therapy to date (21–23). Ongoing research has
attempted to address this fundamental challenge by using nanoparticles as targeted
delivery vehicles. Due to their small sizes and unique shapes, nanoparticles can help steer
a therapeutic load to specific targets and meet a wide range of requirements for
overcoming numerous biological barriers (24–30). There are endless types of
nanoparticle delivery systems, both passive and active, constantly being developed.
Passive systems mostly rely on exploiting the enhanced permeability and retention (EPR)
effect, which exists due to the high leakiness of tumor blood vessels and the lack of a
lymphatic system for drainage (31–34). The delivery specificity can be further improved
by adding an active delivery mechanism, for example, through conjugating nanoparticles
with monoclonal antibodies (mAbs) tailored to recognize over-expressed tumor-specific
biomarkers (35–41). In addition, nanoparticles must be able not only to provide highspecificity targeted delivery but also to ensure that the therapeutic load is not prematurely
released in the plasma or interstitial space before it reaches the intended target (42–45).
Therefore, nanoparticles have been further functionalized to control drug release by
externally applied temperature (46,47), ultrasound (48,49), intracellular pH level (50),
intracellular enzymes (51), or magnetic fields (52–55). Nevertheless, all these approaches
still have inadequately low efficacy.
In parallel, there has been a focus on using the phenomenon of electroporation for
enabling a high-efficacy high-specificity cellular uptake of a drug (56–63). In this case,
an electric field above a cell-specific threshold causes a dielectric breakdown of the cell
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membrane (64). This breakdown field is different for cancer and normal cells of the same
type. For example, application of an electric field on the order of 1 kV/cm can create
sufficiently large pores allowing for an enhanced cellular uptake of molecules by cancer
cells while it takes a factor of two or five higher field to achieve this effect in the normal
cells. Although very promising, the electroporation involves relatively high electric fields
at a relatively large scale and thus comes with collateral damage.
This chapter presents a basic physics model to help understand how a class of
multiferroic nanoparticles known as magnetoelectric nanoparticles (MENs) could address
key challenges in modern cancer therapy (65–73). Indeed, MENs provide (a) targeting
mechanism driven by a physical force rather than antibody matching, (b) a delivery
mechanism that enhances the cellular uptake of a therapeutic load across cancer cell
membranes only, without affecting normal cells, (c) an externally controlled mechanism
that releases the drug-load on demand, last but not least (d) due to the presence of a
magnetic moment, they can be used for image-guided therapy. With the above said,
MENs present a novel platform to treat cancer not from the perspective of bioinformatics
but rather from the perspective of molecular-level physics, such an approach, hereinafter
referred to as technobiology which is complementary to the traditional biotechnology
approach.
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Underlying Physics
Difference between MENs and magnetic nanoparticles (MNPs)
MENs should not be confused with traditional magnetic nanoparticles (MNPs), e.g.,
superparamagnetic

iron

superparamagnetic

and

oxide

nanoparticles

non-superparamagnetic

(SPIONs)

(74–77)

ferromagnetic

or

or

other

ferrimagnetic

nanostructures used for targeted delivery or magnetic imaging (78–81). Like MNPs,
MENs have a non-zero magnetic moment and therefore can be transported via application
of an external d.c. magnetic field with a non-zero spatial gradient. Also, the negative
feedback loop required for image-guided navigation can be closed through existing
magnetic imaging techniques such as magnetic resonance imaging (MRI) or magnetic
particle imaging (MPI) (82–84). However, unlike MNPs, MENs offer a novel
functionality—an energy-efficient control of intrinsic electric fields on the surface of the
nanoparticles via application of external d.c. and a.c. magnetic fields. Due to the
magnetoelectric effect (ME) effect property of MENs, the external magnetic field
controls the electric fields that underlie the intrinsic molecular interactions between
specific cells and the drug-loaded nanoparticles as well as the interaction between MENs
and the loaded drug. An immediate consequence of this capability is the freedom to
engineer an adequately strong bond between the nanoparticles and the drug to avoid an
undesired release of the therapeutic load before it reaches the target; only when an a.c.
magnetic field is applied, this strong bond is “turned off” on demand. This mechanism of
using an a.c. field to controllably break the bond between MENs and the load has been
previously described with regard to the topic of delivery of antiretroviral therapy across
the blood-brain barrier (BBB) to treat HIV-1 virus hidden deep in the brain (85). In
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addition, due to the ME effect, using MENs opens a pathway to exploit intrinsic electric
properties of the cell membrane at the nanoscale for enabling targeted high-specificity
delivery without relying on any bioactive mechanism. The cell membrane, consisting of
numerous ion channels, is an electrically polarizable medium, and its electric charge
strongly depends on the cellular microenvironment, e.g., its pH level. As a result, cellular
properties for cancer and normal cells are significantly different when exposed to local
electric fields (86,87). This difference is the basis for using electroporation for inducing a
high-specificity drug uptake by cancer cells. According to the conventional approach
using electroporation-based cancer treatment, a relatively large electric field, on the order
of 1000 V/cm is applied at the macroscale, which inevitably results in undesired side
effects. With MENs, this property of electroporation can be scaled down to the nanoscale.
As

a

result,

the

MEN-induced

electroporation,

hereinafter

referred

to

as

nanoelectroporation, would result in significantly reduced side effects because the
relatively high field is limited to the nanoscale region in proximity to each nanoparticle.
In addition, the specificity factor (SF), defined as the ratio of the average number of
nanoparticles penetration into a cancer cell versus the average number of nanoparticles
penetration into an adjacent normal cell under equivalent conditions, can be significantly
increased in the case of the nanoelectroporation, as discussed below in more detail. Due
to this nanoelectroporation ability, MENs not only further improve the specificity of the
EPR-based delivery but also add another targeting mechanism to enable passive delivery
at the intracellular level and thus pave a way to treatment of both primary and secondary
tumors at different cancer progression levels. Finally, because of the fundamental nature
of this externally controlled approach, MENs can be used to treat all kinds of cancers

17

including fast-progressing brain tumors and other solid and liquid tumors. Brachytherapy
would be one example of a current approach which could be completely replaced by
MENs. Brachytherapy uses a sealed radioactive pellet, e.g., made of iridium, placed close
to a tumor site through catheters (92). When activated, the pellet emits radiation which
kills both cancer and normal cells a few millimetres away. Using field-activated MENs
instead of the strongly radioactive pellet can significantly improve the specificity of the
treatment and thus reduce or eliminate side effects.

Synthesis and characterization of MENs
MENs can be synthesized according to standard chemical procedures described in
previous studies. One of the most popular room-temperature configurations is the
coreshell nanostructure made of a magnetostrictive core, e.g., CoFe2O4, and a
piezoelectric shell, e.g., BaTiO3 (88–91). By default, in this dissertation, the average size
of MENs is approximately 30 nm and the average size of the core is approximately
10 nm. X-Ray diffraction (XRD) measurements have confirmed the cubic and tetragonal
crystal structures of the core and shell, respectively. Depending on the application,
whether it is for a drug delivery, a neural stimulation, or 3D navigation and/or imaging,
MENs can be further coated with thin functionalization layers serving as linkers to the
therapeutic load or to enable hydrophilic or hydrophobic surface suitable for the
microenvironment of interest. The ME coefficient, α, for these nanostructures is known to
be in a range from 10 to over 100 mV cm−1 Oe−1, depending on the phase compositions
and the quality of the interface between the core and the shell. The saturation
magnetization of these particular MENs is on the order of 10 emu/g, which is an order of
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magnitude smaller than that for high-moment iron oxide nanoparticles. Considering the
core is made of a relatively high anisotropy structure, these MENs are not
superparamagnetic and have a room temperature coercivity on the order of 100 Oe. On a
final note, it is worth noting that in general MENs are not limited to this particular
composition. There are many other compositions which display a non-zero ME effect.
Furthermore, it is likely that in the future MENs will be made of biodegradable organic
materials; for example, carbon based nanostructures which have already been shown to
display a non-zero ME effect (93).

Targeting by MENs
In general, there are two fundamentally different approaches to targeting with MENs,
using local and systemic administration of nanoparticles, respectively. For the local
administration, MENs could be either directly injected into a tumor site or navigated to
the target site via application of localized magnetic fields after the nanoparticles are
administrated in the vasculature. For example, it has been shown that using MRI-guided
navigation with a pulsed sequence of field gradients, magnetic nanoparticles could be
localized at any point in a 3D space with a spatial precision of less than 0.1 mm (94). For
the systemic administration, MENs could be administrated intravenously. In either case,
the delivery and uptake specificity could be further significantly improved due to the
following physics.
Unlike purely active delivery approaches, e.g., using mAbs, T-cells (CAR TCell), or cancer vaccines, MENs offer a passive delivery mechanism, which is
complementary to the well-known EPR effect (95). The EPR effect ensures delivery of
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drug-loaded nanoparticles into relatively large tumor aggregates but not in relatively
small aggregates made of one or few cancer cells. In contrast, due to a different
underlying physics, MENs-driven targeting works equally well with cell aggregates and
individual cells. Because MENs generate their own electric fields, which in turn can be
controlled by external magnetic fields, they can specifically electroporate cancer cells
only without affecting surrounding normal cells, as described below in more detail. In
this case, the localization range of the nanoparticle-generated electric field is defined by
the nanoparticle's average size, which is approximately 30 nm. In turn, this localization
range is orders of magnitude smaller than the characteristic cell size, which is on the
order of a few microns. Therefore, MENs could be used to target primary and
metastasized cancer cells even at a very early stage of cancer progression. Last but not
least, because of the existence of an externally controlled surface charge, MENs bring
another dimension to targeted delivery; not only can they increase the specificity factor
but also can provide new functions of externally controlled cancer cell penetration and
drug release via application of external magnetic fields. In a trivial approximation, the
electric field generated by a MEN at a point on the cell membrane consists of two terms:
E=k
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()
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r̂ ,

(1)

where k is the Coulomb constant, Q and p are the MEN's electric charge and
dipole moment, respectively, and r is the distance between the nanoparticle and the
observation point on the membrane. The first term is determined by the magnetic-field
dependent electric dipole moment due to the ME effect, p = αH, where α is the ME
coefficient and H is the external magnetic field. The second term is determined by the
surface electric charge which is formed according to the colloidal chemistry when MENs
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are placed in a solution, e.g., the blood or the lymph. In this case, a double charged layer
is formed around the nanoparticle's surface because of the interplay of chemical and
electrical forces. The surface charge can be determined by measuring Zeta potential.
Furthermore, previously it has been shown that this surface charge can be further
increased with an external magnetic field increase; in other words, the field dependence
of the surface charge also depends on the ME effect. It can be noted that the surface
charge term has a more significant effect because it drops with a distance substantially
slower (∼1/r2) compared to the dipole charge term (∼1/r3).
Because both MENs and the cell membranes have the same charge polarity,
MENs can easily go through a capillary without being engulfed by the surrounding cells.
However, when MENs are in close proximity to the cell membranes (within a distance on
the order of a micron), their electric field (on the order of 0.1 V/µm, as shown below
mostly due to the charge) is sufficiently strong to induce a local dielectric breakdown in
the cancer cells but not too strong (≲1.5 V/µm) where it may cause this effect in the
normal cells. This dielectric breakdown is reflected in a local change of the lipid bilayer
of the cellular membrane. Such a field-dependent local change leads to cellular uptake of
the drug-loaded nanoparticles through the membrane surface. Indeed, it is known that the
conductivity of the intermediate cancer cell membrane is by three orders of magnitude
larger than that of the normal cell membrane (97). The high-conductivity membrane
induces a local attraction force between MENs and the cancer cell due to the electrostatic
“mirror” effect. Here, it is worth noting that this nanoelectroporation effect could be
further increased through application of a pulsed magnetic field sequence. In this case,
the intermediate high-conductivity breakdown state effectively lasts longer and thus the
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efficacy of this treatment is significantly increased. That is the reason why the a.c. field
application might be more effective compared to the d.c. field application. However, to
simplify the explanation, the following description is focused on the d.c. case. In a first
order approximation, there are two distinct states of the membrane. In its normal state,
the membrane is non-conducting. In this case, the negatively charged MENs are pushed
away from the negatively charged membrane surface. On the contrary, during the
intermediate nanoelectroporation process, the membrane surface of the cancer cells is
conducting and thus MENs are attracted to the cancer cells. According to the “mirror
image” model, the attraction force could be estimated with this expression,
Fmirror=kQ2/4r2,

(2)

where the factor ¼ is due to the fact that the effective distance between the real
and image charges is 2r, while r is the distance between the nanoparticle and the
membrane surface. Furthermore, as previously shown, the effective surface charge and
thus this attraction force can be further increased with an increase in the externally
applied magnetic field. This magnetic field dependence of the charge can be found
through an experimental measurement of Zeta potential, V(H), in a phosphate buffer
solution (PBS) with a pH level similar to that in the blood, Q = V(H)d/k. Now, it is
possible to estimate the cut-off distance between the nanoparticle and the membrane
surface, rC, below which the electric field would be above the nanoelectroporation
threshold on the order of 0.1 V/µm for the cancer cells: rC = 0.5(kQ/E)1/2. For example, it
has been shown that application of a magnetic field on the order of 300 Oe could increase
the cut-off distance by a factor of two. Such an increase would significantly increase the
number of the nanoparticles capable of triggering local nanoelectroporation and
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consequently would significantly increase the specificity factor of targeted delivery. This
concept of MEN-based targeting is illustrated in Figure 1. It could be noted that this
overly simplified theory does not take into account the laminar flow in the circulation.

(a)

(b)

Figure 2.1. Illustration of the dependence of the cutoff distance, rc, on application of an external
d.c. magnetic field,H. (a) The nanoparticles within this distance from the membrane surface target
the cancer cells due to the high-specificity nanoelectroporation effect. (b) The distance is increased with an
increase in the magnetic field.

On-demand drug release by MENs
After the drug-loaded MENs enter the cancer cells, the drug can be released off the
nanoparticles on demand via application of an a.c. external magnetic field. In this case, as
previously shown, even a relatively small magnitude a.c. field (≲50 Oe) in the near-d.c.
frequency ranging from 10 to over 100 Hz is sufficiently strong to release substantial
amount of the drug into the cancer cells. It has been hypothesized that application of an
a.c. field “shakes” the drug off the nanoparticles by significantly weakening the electricfield bond which holds the two together, as illustrated in Fig. 2.2 According to the trivial
model, the electric dipole moment induced by an external magnetic field due to the ME.
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effect is ΔP = αH; therefore, the displaced surface charge density on the diametrically
opposite side of the nanoparticle would be σME ∼ ±αH. In other words, the magnetically
triggered electric dipole moment breaks the symmetry of ionic bonds around the
nanoparticle. To a zeroth approximation, when the displaced surface charge is
comparable to the charge involved in an original bond, σME ∼ Qionic/πd2, the bond can
be broken. Then, the threshold magnetic field amplitude to break a bond can be evaluated
according to this simple expression:
Hth ∼Qionic/πd2α,

(3)

where d is the diameter of the nanoparticle, α is the ME coefficient, and Qionic is the
displaced charge in the ionic bond. Application of an a.c. field would break the bonds in
all the orientations around the nanoparticle.

Figure 2.2. Illustration of the drug release mechanism
via application of an a.c. magnetic field.

Here, it is worth reminding that it is imperative to release the drug off MENs to increase
the drug bioactivity only after the drug-loaded MENs penetrate the cancer cells(76). In
other words, MENs enable a drug retention control via application of external magnetic
fields; the initial step of high-specificity cellular penetration and the final step of drug
release off MENs are triggered via application of d.c. and a.c. fields, respectively.
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In summary, the above described three-step field-controlled process for targeted drug
delivery and release, respectively, is illustrated in Fig. 2.3.

Figure 2.3. Illustration of targeted and release mechanism of
delivering a therapeutic load to a cancer cell.

Supporting Experiments
Confocal microscopy study of high-specificity cellular penetration
The purpose of the first described in vitro experiment was to show how an external d.c.
magnetic field could be used to induce a penetration of drug-loaded MENs into cancer
cells. A popular mitotic inhibitor paclitaxel (PTX) was used as the therapeutic load. In the
described microscopy experiments, the PTX's fluorescent version known as Flutax-2 was
imaged at 488 nm (green color). A multidrug resistant cancer cell line MES-SA/DX5 was
used to test the field-induced penetration. For comparison, similar images were taken for
two other cases with cells incubated under equivalent conditions without any drug and
just with the drug, respectively. Microscopy images of the two control cases and the cells
incubated with MENs without and with exposure to a d.c. field of 30 Oe for
approximately 12 h are shown in Figs. 2.4(a)–2.4(d), respectively. The optically
measured percentages of the drug uptake per mg of protein in the four cases were 0, less
than 0.3%, less than 0.2%, and more than 6%, respectively. According to the procedures
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of the experiment, the green light could be seen only from the drug coming from inside
the cells, because all the extracellular material was washed away. The experiment clearly
showed a strong field dependence of the cellular uptake of the drug-loaded MENs.
Indeed, the uptake of the drug increased from less than 0.2% to over 6%, i.e., by a factor
of 30, after application of a relatively small d.c. field of 30 Oe.

Figure 2.4. Confocal microscopy imaging of the uptake of Flutax-2 by cell line
MES-SA/DX5 for four different drug-delivery-system combinations: (a) no drug,
(b) free Flutax-2 (drug uptake per mg of protein: <0.3%), (c) MENs loaded with
Flutax-2 with no field (<0.2%), and (d) MENs loaded with Flutax-2 in a 30 Oe d.c.
field (>6%). The scale bar is approximately 50 um.

Another experiment was conducted to demonstrate a high-specificity cellular uptake with
MEN-based delivery on ovarian cancer and normal cell lines SKOV-3 and HOMEC,
respectively. The optically measured drug uptake depending on the applied d.c. magnetic
field for cancer and normal cells is shown in Fig. 2.5. Indeed, it could be observed that
there was a significant field range, from ∼50 Oe to ∼500 Oe, when visibly large amount of
the drug penetrated the cancer cells while barely any drug penetrated the normal cells. As
mentioned earlier, the effect of nanoelectroporation could be further increased via
application of a periodic sequence of magnetic field pulses to effectively prolong the
membrane's intermediate dielectric breakdown state which leads to the nanoparticles'
cellular uptake. Application of an a.c. magnetic field partially mimics this pulsed
sequence effect (53). Indeed, this a.c. field dependence was demonstrated in this study.
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Figure 2.5. Optically measured (with a fluorometer) field
dependence of the drug uptake per mg of protein for
cancer and normal cell lines SKOV-3 and HOMEC,
respectively.

Another experiment which demonstrated the field-dependent cellular penetration of
MENs was conducted with atomic force microscopy (AFM) and magnetic force
microscopy (MFM) imaging of cell lysates. This experiment directly confirmed the
presence of MENs inside cancer cells only after application of a 100-Oe d.c. field.

Drug release off MENs via application of an a.c. field
The purpose of the following experiments was to prove that the therapeutic load could be
released off MENs via application of an a.c. magnetic field. Consequently, the function
of the drug release could be physically separated from the function of high-specificity
targeting, in turn, achieved via application of a d.c. field.
In one experiment, the amount of the released drug (paclitaxel) was measured
spectrophotometrically at its maximum absorption wavelength of approximately 230 nm.
It is known that the bioactivity of the drug significantly increases after the release due to
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the increased “free” surface area. The dependence of the released drug on the strength
and frequency of the a.c. field ranging from 12 to 66 Oe and 0 to 1000 Hz, respectively,
for different application times ranging from 1 min to 2 h, is shown in a chart in Fig. 2.6.

Figure 2.6. The dependence of the release of the drug,
paclitaxel, on the a.c. field strength and frequency for five
different application times: 1, 5, 10, 60, and 120 min. The
data were measured spectrophotometrically as the absorbance
at 230 nm wavelength.

Liquid-environment atomic force microscopy study of the nanoparticle-cell interaction
A liquid environment atomic force microscopy (AFM) study was conducted with the goal
to directly measure the surface of cancer and normal cells under different experimental
conditions. In the following experiment, glioblastoma (U87-MG) and endothelial cells
were used as the cancer and normal cells, respectively. Glioblastomas represent the most
frequent primary brain tumors while endothelial cells are characteristic normal brain
cells. It was already demonstrated that drug-loaded MENs could be navigated across the
blood-brain barrier (BBB) via application of a sufficiently strong d.c. magnetic field
gradient (on the order of 1000 Oe/cm) with the subsequent controlled release of the drug
after the nanoparticles are placed deep in the brain (85). Typical AFM images of
endothelial and glioblastoma cells are shown in Figs. 2.7(a) and (b), respectively. It can
be noted that the normal cells have a more continuous surface morphology compared to
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the cancer cells with clearly visible striations with a characteristic size on the order of
100 nm.

(a)

(b)

Striations

Figure 2.7. AFM image pair (z height and phase (right)) for (a) endothelial and (b) glioblastoma cells.

Another AFM experiment was conducted to understand how MENs penetrated the cancer
cells. MENs were added into media with glioblastoma cells through a special Multimode
liquid environment microprobe container. Here, it is worth noting that usually when
nanoparticles or other nanoscale foreign reagents get attached to the membrane surface,
they quite rapidly (within seconds) move across the membrane and penetrate the cell. The
exact origin of this process still remains an open question; it might be defined either by a
chain signaling between biomolecules within the cell or by some electric field effects in
the membrane and the cellular plasma or a combination of these two effects. It is not
trivial to use AFM to observe the fast dynamic of the nanoparticle-cell interaction. To
slow down the cellular uptake of the nanoparticles, this experiment was conducted at a
relatively high concentration of MENs to ensure the cells are saturated and as a result the
nanoparticles become visible on the membrane surface. An important observation of this
experiment was the fact that the nanoparticles preferred to penetrate the cancer cell
through the striations in the cellular membrane, as shown in Fig. 2.8.
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Figure 2.8. AFM image pair (z height and phase (right))
for glioblastoma cells with MENs found in striations on
the surface membrane. The observed nanoparticles are
approximately 30-nm in diameter.

Finally, it could be mentioned that MENs operate at relatively low fields and frequencies
and thus do not cause significant heating effects, as was confirmed through infrared
measurements of the cell surface at different concentrations of MENs under different
field exposures

Conclusion
The discussed experiments have demonstrated that MENs could be used for externally
controlled targeted drug delivery and release. Furthermore, these two important
functions, i.e., delivery and release, could be physically separated via application of d.c.
and a.c. external magnetic fields, respectively, as indicated by the hypothesized theory
and confirmed by a number of independent experiments. For example, confocal
microscopy studies have directly confirmed that the penetration of MENs into cancer
cells occurs only after the application of a d.c. magnetic field on the order 100 Oe, while
numerous spectrophotometry measurements have shown that the drug is released off the
nanoparticles only after the application of an a.c. magnetic field with a strength on the
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order of 50 Oe and a near-d.c. frequency of 100 Hz. As for the high-specificity delivery,
one of the most important characteristics of MENs is their ability to deliver drugs
specifically into the cancer cells without affecting the surrounding normal cells. The
penetration fields due to the nanoelectroporation, i.e., the mechanism according to which
the delivery takes place, are different for the two cell forms, i.e., cancer and normal cells,
respectively, because their membranes have different surface morphologies and charge
configurations, as shown through transport measurements and AFM studies. As a result,
it takes a significantly higher field to break the dielectric barrier of the normal cell
membranes compared to that of the cancer cells. As mentioned above, it is well known
that even at the macroscale, the cancer cells have a smaller threshold field for the
electroporation compared to their normal counterparts; the difference is a factor of two to
five depending on the cancer type. The discussed experiments with MENs have shown
that at the nanoscale the difference becomes even more significant. For example, for the
ovarian and normal cancer cell lines, SKOV-3 and HOMEC, respectively, it takes less
than 100 Oe and significantly more than 1000 Oe, respectively, to induce the
nanoelectroporation via the ME effect. That is the reason why we refer to the
electroporation (by MENs) at the nanoscale as the nanoelectroporation. The
nanoelectroporation seems to have a significantly higher specificity factor compared to
the traditional electroporation effect which takes place at the macroscale. The AFM
imaging of equivalent glioblastoma cancer and normal endothelial cells has shown very
different surface topographies for the two cell types; the normal cells are more
continuous compared to the cancer cells which in turn have visible striations of the
characteristic size on the order of 100 nm. The AFM images have also shown that 30-nm
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MENs tend to accumulate in these striations and thus penetrate the cell through these
striations. The fact that the nanoparticles penetrate the cancer cells through the small
striations in the membrane might explain why the ratio between the nanoelectroporation
threshold fields between cancer and normal cells is more significant (≳10) compared to
that for the traditional electroporation at the macroscale (∼2–5). It is worth noting that
due to the intrinsic nature of the ME coupling in the multiferroic nanostructures, the
magnetic field strength on the order of 100 Oe, required for enabling the high-specificity
delivery and release functions, is substantially below any harmful limits as per US Food
and Drug Administration (FDA) regulations (98). Eventually, because of the fundamental
nature of this approach, it can be applied to any cancer type. Last but not least, it can be
mentioned that most current studies have been performed with MENs of the same
coreshell composition, i.e., CoFe2O4–BaTiO3. These experiments have been vital to
demonstrate the feasibility of the MEN-based cancer treatment approaches. In the future,
other compositions can be explored, e.g., ones made of biodegradable organic materials.
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Materials and procedures
Chemical synthesis of MENs
CoFe2O4-BaTiO3 core shell MENs were prepared according to a polyvinylpyrrolidone
assisted hydrothermal method. First, 0.058 g of Cobalt Nitrate Hexahydrate
(Co(NO3)2·6H20) and 0.16 g of Ferric Nitrate Nonahydrate (Fe(NO3)3·9H20) were
dissolved by stirring in 15 ml of distilled water. Polyvinylpyrrolidone (PVP), 0.2 g, was
dissolved in 5 ml of aqueous solution containing 0.9 g of sodium borohydride. The PVPsodium borohydride solution was added dropwise to the above solution and the mixture
was stirred at 120 °C until the liquid phase evaporated. CoFe2O4 particles were
recovered, dispersed in distilled water through sonication, and washed 3 times using
magnetic separation. Purified CoFe2O4 cores were dried at 120 °C for 24 h and stored at
room temperature until further use. The Barium Titanate (BaTiO3) shell was prepared
using the citrate gel method. Briefly, CoFe2O4 cores were dispersed in distilled water
through sonication. Barium Carbonate (BaCO3), 174 mg, was dissolved in 60 ml
deionized water containing 1 g of citric acid. This solution was mixed with a 150 ml
ethanolic solution of titanium (IV) isopropoxide (284 µl) and 6 g citric acid. The BaTi
precursor solution was added to the cores and sonicated at room temperature for 1 h. The
translucent yellow liquid was stirred at 70 °C until the liquid phase evaporated
completely. Finally, the gel was calcined at various temperatures ranging from 500 to
800 °C (CMF-1100) for 5 h and cooled naturally to room temperature. The gelation
temperature and the final temperature were important determinants of the crystal
structure and the final size of CoFe2O4-BaTiO3 core shell MENs. For example, a
temperature of 600 °C was required for 30-nm MENs.
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Atomic force microscopy
The imaging of both glioblastoma and brain endothelia cells in a cellular
microenvironment was conducted using a MultiMode AFM system. Using a Bruker
electrochemistry fluid cell probe holder that has an integrated piezo element for contact
mode experiments and Bruker's DNP-S10 silicon nitride probe, we were able to achieve
the desired results showing the interaction between MENs and the surface of a cell. The
DNP-S10 probe comes with four different cantilevers of various dimensions each having
a different nominal spring constant value and resonant frequency. The special C
triangular shape cantilever was used for cell imaging; the cantilever has a nominal
resonant frequency of 56 kHz and a nominal spring constant of 0.24N/m which are ideal
values for imaging stiff and firmly attached samples. After placing the probe in the liquid
solution, which for this experiment was phosphate buffer solution (PBS), the resonant
frequency dropped to 8 kHz, i.e., an order of magnitude lower compared to the frequency
in air. After obtaining a lower resonant frequency, the probe was engaged with the
membrane surface for scanning at a frequency rate of 0.100 Hz and a scan size of 100 nm;
these two parameters were gradually increased until an adequate quality image was
obtained.
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CHAPTER III: NUCLEAR MAGNETIC RESOSNACE SENSITIVE NANOPROBE
FOR CANCER CELL DETECTION BY MEGNETOELECTRIC NANOPARTICLES
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Introduction
Expedited detection of cancer is the first step in creating a cancer-free world. Research
has shown that early detection and treatment of premalignant abnormal cells can prevent
most cancer deaths from occurring. However, traditional techniques which rely on
biochemical staining require a tedious sample preparation and are limited to a few
biomarkers. As a result, there have been increased interests in magnetic nanoparticle bio
sensing (MNPsB). Due to the external control of the magnetic moment, MNPsB promises
to enable high-specificity screening and rapid diagnostics of carcinomas (99-103).
However, the current progress in this area remains relatively slow; the main challenge is
coupling the intrinsic cellular information to the magnetic nanoparticle with high
efficiency to process the information with current magnetic detecting systems. In the
cellular microenvironment each cell structure is characterized by a certain membrane
surface morphology, which results in a signature electric field configuration based on cell
type and prognosis stage. While current system measures magnetic fields, the intrinsic
cellular information is reflected in electric fields that traditional MNPs are unable to
translate (104, 105). To address this problem, we propose using multiferroic
nanostructures known as magnetoelectric nanoparticles (MENs) capable of coupling the
electric signature of cancer cells, which is based on cell type and prognosis stage, to the
magnetoelectric effect property of the nanoparticles(106-110). MENs have proven to
have magnetic and electric dipole moments which are correlated through the ME effect
(66-69). Due to the electric charge interaction of the nanoparticle and the cellular
membrane, the nanoparticle tends to attach to specific cell sites. This attachment provides
access to the cells’ intrinsic cellular information, which can be converted due to the ME
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effect and processed using current magnetic detectors. The ME effect created by a
ferroelectric phase shift on the nanoparticle (from the cellular membrane) to the
ferromagnetic core of the nanoparticle which allows the intrinsic electric field
information of the cell to be translated into specific magnet field patterns, capable of
being measured using current magnetic detection systems i.e. NMR systems.
Experimental Results
For comparison, MENs and conventional MNPs were integrated into media with different
cancer and normal cells and measured in a NMR spectra under equivalent conditions.
Specifically, the mean diameter of the core-shell MENs (CoFe2O4@BaTiO3) were
30±6nm and displayed a strong ME effect. Compared to that of the ferromagnetic MNPs
(CoFe2O4) with a diameter of 15±4nm and displayed no ME effect.

Figure 3.1a and b show room-temperature M-H hysteresis loops of MNPs and MENs,
respectively, measured using vibrating sample magnetometry (VSM) system. The M-H
hysteresis loop measures how much magnetic energy is required to align the dipole
moment of a ferromagnetic material. During this measurement, once a critical field is
applied to the ferromagnetic material, a saturated state is formed and the dipole moment
is completely aligned with the external field causing the magnetization of the material.
During magnetization, the material is magnetized indefinitely, even after removing the
external magnetic field. To demagnetize the material, which depends exclusively on the
coericivity of the material; heat or a much higher external magnetic field in the opposite
direction must be applied. Despite the fact that the magnetic components in the two cases
were equivalent, according to the magnetic hysteresis loops, MNPs and MENs had
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saturation magnetizations of approximately 40 and 1 emu g−1, respectively, and coercivity
fields of approximately 90 and 310 Oe, respectively. To understand the MENs’
temperature dependence and measure the transition into the superparamagnetic mode. In
the case of superparamagnetic mode the nanoparticle is no longer stable, meaning the
orientation of the magnetic dipole moment will began to randomly flip under the
influence of temperature. Typical M-H hysteresis loops of MENs in a temperature range
from 4 to 300 K were obtained via a cryogenic vibrating sample magnetometer Quantum
Design PPMS. The standard magnetization versus temperature curves under zero field
cooling (ZFC) and non-zero field cooling (FC) conditions that determine the blocking
temperature are shown in Fig. 3.1d. The blocking temperature is the temperature above
which the nanoparticles become superparamagnetic. In this case, it is above 300 K, which
confirms that the magnetic cores of MENs do not become superparamagnetic at room
temperature despite their small size. The ME coefficient, α, for these nanostructures has
been previously measured to be in the range from 10 to over 100 mV cm−1 Oe−1.

Figure 3.1. Characterization measurements of MENs. Room-temperature M-H hysteresis
loops of (a) 30-nm MENs and (b) 15-nm MNPs. (c) Shows A TEM image showing a
coreshell structure of 30-nm MENs. (d) Blocking temperature measurement curves
including zero-field cooling (ZFC) and field cooling (FC) curves in a field of 100 Oe.

38

Figure 3.2 shows continuous wave NMR (CW-NMR) spectra for three cancer and one
normal cell lines under study, including ovarian carcinoma cells Skov3, glioblastoma
cells U87-MG, breast adenocarcinoma cells MCF-7, and normal brain endothelial cells,
respectively, all without any nanoparticles being present. Nuclear magnetic resonance
spectroscopy is a technique that exploits the magnetic properties of certain atomic nuclei,
which in turn provides physical and chemical information about the material. In our case,
the NMR spectrum represents a chemical shift due to intrinsic molecular interactions,
which was measured as an absorption energy in the field sweep range from −5G to +5G
and at a frequency of 14,000 KHz. It can be noted that the four cell lines do not
significantly differ from each other.

Figure 3.2. CW-NMR spectra of cell media without MENs for four types of cells: (i)
ovarian carcinoma cells Skov3, (ii) glioblastoma cells U87-MG, and (iii) breast
adenocarcinoma cells MCF-7, respectively, and (iv) normal brain endothelial cells.
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Figure 3.3a–d show four sets of CW-NMR spectra of media obtained by incubating the
above three cancer cell lines and one non-cancerous normal cell line, respectively, for
15 hours with traditional MNPs. Each set consists of three curves including spectra for
cells only, cells incubated with MNPs without the application of an external field, and
cells incubated with MNPs under application of a 100 Oe d.c. magnetic field. The
concentration of the nanoparticles in each media was approximately 150 µg ml−1. Similar
to the case without any nanoparticles, neither of the spectra (i.e. cells + MNPs and
cells + MNPs + Field) for the four cell lines significantly differs from the corresponding
cell line without MNPs incubation as well as between each other.

Figure 3.3. CW-NMR spectra including cells only, cells incubated with MNPs without
and with application of a 100-Oe d.c. field for (a) glioblastoma cells U87-MG, (b)
ovarian carcinoma cells Skov3, (c) breast adenocarcinoma cells MCF-7, respectively, and
(d) normal
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However, this trend changes when MENs are used instead of MNPs. Figure 3.4 shows
CW-NMR spectra obtained by incubating the same three cancer cell lines and noncancerous cell line for the same amount of time (15 hours), with the only exception of
having MENs instead of MNPs at the same concentration of approximately 150 µg ml−1.
According to these spectra, in great contrast to the traditional MNPs, MENs significantly
affect the NMR spectrum for each cancer cell type. The only exception is the noncancerous endothelial cell line; as MNPs, MENs barely affected the spectrum. For
comparison, Fig. 3.5 shows NMR spectra for the same three cancer cell lines incubated
with MENs without field application under equivalent conditions with the nanoparticle
concentration of approximately 150 µg ml−1. Again, unlike the previous case with the
traditional MNPs and NMR spectra for the three cancer cell lines are very different from
each other as much as they are different from their normal counterparts. It can be noted
that the difference between the spectra is not just quantitative but rather qualitative. Each
cell type displays a distinguished set of peaks in its spectrum, thus indicating an intrinsic
interaction between MENs and cells.
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Figure 3.4. CW-NMR spectra including cells only, cells incubated with MENs for (a)
glioblastoma cells U87-MG, (b) ovarian carcinoma cells Skov3, (c) breast
adenocarcinoma cells MCF-7, respectively, and (d) normal brain endothelial cells.
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Figure 3.5. CW-NMR spectra of cell media with MENs for cancer cells.
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Figure 3.6a–d show atomic force microscopy (AFM) images of the membrane surfaces of
normal brain endothelial cells with nanoparticles (a,b), brain endothelial cells
with/without nanoparticles, and glioblastoma cells in the presence of MENs (c,d),
respectively. Each pair of scans represents z-height and phase images, respectively. The
nanoparticles, represented by circled dotted lines, can be seen only in the glioblastoma
images. Indicating the field applied was not sufficiently strong for MENs to effect the
electric charge of the cellular membrane of the non-cancerous normal cell. It can be noted
that the membranes of normal endothelial cells have a more continuous surface, unlike
the membranes of glioblastoma cells which have clearly visible membrane striations with
a characteristic size on the order of 100 nm or smaller. From the visual MENs seem to be
associated with the striations.
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Figure 3.6. AFM images of the membrane surfaces of (a) normal brain endothelial cells,
(b) normal brain endothelial cells with MENs at a saturated concentration (c)
glioblastoma cells and (d) glioblastoma cells with MENs at a saturated concentration
level.
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Discussion
Cellular uptake of nanoparticles is a thermodynamic phenomenon that occurs from
nanoparticle adsorption on the cell membrane followed by membrane wrapping and
invagination in order to minimize the chemical binding energy (114-119). As a reminder,
MENs should not be confused with traditional MNPs. Despite the difference in
magnetization saturation, where MNPs has a saturation magnetization of 40 emu g−1 and
MENs only a 1 emu g−1, MENs evidently have a strong effect on the NMR response with
or without an external magnetic field applied. This indicates the importance of the nonzero magnetoelectric (ME) effect of MENs compared to MNPs. When MENs are added
into the polarized electric system of the cellular microenvironment, the binding
interaction between the nanoparticle and cell cause the energy associated with the cell to
be minimized, expressed as absorption energy on the CW-NMR spectroscope.
Furthermore, depending on the binding sites or uptake mechanism, the intrinsic electric
fields are affected in a specific way due to the electrostatic and chemical bonds at these
sites. Due to the ME effect, the resulting change in the electric field triggers a change in
the magnetic moment of the nanoparticle, which in turn induces a change of the local
magnetic field at this location. Since the concentration of nanoparticles in the
extracellular medium is very high compared to the number of cells, the adsorption of
nanoparticles on cell membrane is saturated at long periods of incubation (120-123). The
AFM images indeed show that MENs are attached to the membrane of glioblastoma cells.
The distinct organization of MENs around glioblastoma and brain endothelial cells was
further verified by fluorescence images of these cells incubated with fluorescein
isothiocyanate loaded MENs. For nanoparticles with a negative zeta potential, the cellular
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uptake is strongly dependent on the cell type, the organization of nanoparticles on the
membrane surface also depends on the cell type and the mode of uptake. Therefore, this
would change the local net magnetic field in a very specific way depending on all the
aforementioned cellular properties. Below, a simple analysis is presented to quantify the
resulting change in the local net magnetic field, which in turn is observed as the
appearance of new shifts in the NMR spectrum.
Each binding site contributes to the net NMR signal; the contribution, i.e. the
electromagnetic energy absorption at this site, is generated when the following resonance
condition is satisfied: hω = SnHnet, where h is the Plank constant, ω is the frequency of the
electromagnetic wave, Sn is the magnetic moment of the measured nuclear spin (in this
study, the proton spin); Hnet is the net magnetic field at this location. This local net field
is made of two contributions, (i) the external field generated by the NMR magnets, H0,
and (ii) the field due to the ME effect of MENs at the site, HME , respectively:

Hnet=H0+HME.
To a zeroth approximation, in the vicinity of a nanoparticle, HME ~ΔMS = αE, where
ΔMS is the nanoparticle’s saturation magnetization, α is the ME coefficient, and E is the
electric field in the vicinity of the nanoparticle. In turn, this electric field depends on the
cell membrane morphology. According to this logic, due to the non-zero ME effect, the
measured spectrum shifts on the order of 1 Oe should reflect contributions of MENs from
different binding sites (Fig. 3.3). This is the reason for a significant dependence on the
cell type and indeed the resulting changes of spectral shifts are on the order of 1 Oe. It
also follows that the traditional purely magnetic nanoparticles, i.e. MNPs, which do not

47

display any ME effect, could not provide this intrinsic contribution specific to each cell
type, despite the fact that their saturation magnetization is almost two orders of
magnitude higher than that for MENs (Fig. 3.3a,b). To evaluate the approximate value of
the average magnetoelectrically induced electric field, E, that holds MENs attached to the
cell and thus results in the observed spectrum shift on the order of 1 Oe, we can assume
α~100 mV Oe−1 cm−1, ΔMS ~1 emu cc−1. Then, E~10 V cm−1. In summary, the above
comparison indicates that it is due to the ME effect that the observed signature NMR
spectra of each cell line investigated occurred. According to the hypothesis, with the
introduction of MENs in a saturated state, the relative modification of the averaged NMR
energy could be evaluated using a trivial expression; WMENs~αESnA, where A is a
constant between 0 and 1 which represents the relative surface area covered by the
striations, which in turn strongly depends on the cancer cell type and the cancer
progression stage.

To more directly represent the observed energy dynamics in the measured NMR
spectra, an inverse Fourier Transform (IFT) operation was performed on the spectra. It
can be noted that a CW-NMR spectrum represents a signal in the frequency domain while
IFT curve represents the same signal in the time domain. The decaying IFT amplitudes
for the cell lines under study are shown in Fig. 3.7. The decay of the IFT curves clearly
show how distinguished the spectra for all the cell lines under study are, particularly in
the presence of MENs. It can be noted that the time dynamic doesn’t change when cells
are incubated with MNPs while the NMR-associated energy transfer process for
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establishing an equilibrium is at least 5 to 20 ms faster when cells are incubated with
MENs based on the cell type, as summarized in Table 1.

Figure 3.7. Inverse Fourier Transform (IFT) representation of CW-NMR spectra for
Glioblastoma Brain EC, Skov3 and MCF7 with MENs and MNPs. The straight dotted
slope lines indicate the approximate equilibration time for each type of measurement.
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Table 1: Characteristic time-constant for different cellnanoparticle combination

Conclusion
Multiferroic core-shell magnetoelectric nanoparticles with a diameter of 30 nm’s were
fabricated through a standard hydrothermal synthesis. The coupled magnetic and electric
phases, due to its’ multiferroic properties, categories these nanoparticles in a class of their
own. Particle adsorption on the cell membrane was dependent on the membrane
morphology, which was based on the cell type as observed under live-cell AFM imaging.
Due to the distinct association with cells and the ME effect the NMR adsorption spectra
for cells incubated with MENs was significantly different compared to cells without any
MENs.

Materials and Procedures
Magnetoelectric nanoparticles preparation and characterization
CoFe2O4-BaTiO3 core shell MENs were prepared according to the following procedure.
As the first step, the cores of CoFe2O4 were prepared by the standard hydrothermal
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method, according to which 0.058 g of cobalt (II) nitrate hexahydrate Co(NO3)2.6H20 and
0.16 g of Iron (III) nitrate nonahydrate Fe(NO3)3.9H20 were dissolved in 15 ml of
distilled water and 0.2 g of polyvinylpyrrolidone was dissolved in 5 ml of aqueous
solution containing 0.9 g of sodium borohydride at 120 °C for 12 hours. For shell growth
around the cores, a precursor solution of BaTiO3 was prepared by mixing 30 ml of
aqueous solution containing 0.029 g of BaCO3 and 0.1 g of citric acid with 30 ml of
ethanolic solution containing 1 g of citric acid and 0.048 ml of titanium (IV)
isopropoxide. Coreshell CoFe2O4-BaTiO3 MENs were prepared by mixing 0.1 g of
CoFe2O4 nanoparticles in the BaTiO3 precursor solution and the mixture was sonicated
for 2 hrs. Once the CoFe2O4 nanoparticles were thoroughly dispersed, the mixture was
dried on the hot plate at 60 °C overnight while being continuously stirred. The dried
powder was heated to 780 °C for 5 hrs. in a furnace (CMF-1100) and cooled at 5 °C per
minute to obtain coreshell MENs of ~30 nm diameter. The particles size distribution was
measured using dynamic light scattering method (Malvern-Zetasizer) and through
transmission electron microscopy.

Cell culture and sample preparation CW-NMR
All in-vitro cell experiments and biological material handling were approved and
performed in accordance within the set guidelines of Florida International University.
Three cancerous cell lines including Skov3 (Ovarian adenocarcinoma) (ATCC;
Manassas, VA), U87-MG (Glioblastoma) (ATCC), MCF-7A (Breast adenocarcinoma)
(ATCC), respectively, and two non-cancerous cell lines including brain endothelial cells
(Brain EC, ATCC) and rat smooth muscle endothelial cells (RSMC, ATCC),
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respectively, were cultured at 37 °C as per manufacturer’s instructions. For nanoparticle
studies, cells were detached using 0.25% trypsin solution, plated in 6 well plates and
allowed to grow to 80% confluency. MENs were resuspended in cell culture media
through sonication and were incubated for 30 minutes. MENs were added to each well at
a concentration of 150 µg/ml and the cells were further incubated for 15 hours, to allow
attachment of MENs with the cells. Additionally, all the cell lines were incubated with
150 µg/ml traditional MNP (CoFe2O4) for 15 hours. In order to increase the interaction of
MNP’s with cell membrane a d.c magnetic field was also applied. Cells incubated with
MNPs were placed at a distance from a d.c magnet, directly underneath the culture plate.
The distance of magnet from cell culture plate needed to create 100 Oe field was
determined using a gauss meter. After the end of incubation period, the cells were washed
with phosphate buffered saline (PBS) to remove particles not strongly bound to cells.
Cells were scraped from the bottom of plate and transferred to a 5 mm NMR tube.
Continuous wave- 1H NMR spectra were obtained using a continuous wave (CW)
spectroscope. Sample placement, instrument parameters (B0, instrument phase, linewidth) were carefully selected to ensure optimal signal to noise ratio. Each NMR
spectrum was collected at opposite phases (in our case these were 107 and 297). Signal
processing such as solvent suppression, baseline correction and inverse fourier transform
were performed in MATLAB® (Mathworks, MA)
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Atomic force microscopy imaging
U-87 MG and Brain endothelial cells were grown on poly-l-lysine coated cover slips and
were incubated with MENs similarly as described above. After the incubation, the
coverslips were washed with phosphate buffered saline (PBS) and were transferred to
stubs. The live cell/wet atomic force microscopy (AFM) mode of a Multimode was used
to obtain AFM images of cells with Bruker AFM probes DNP-S10 using a three-port
electrochemistry tapping fluid cell element ECFC. The cantilever C had a resonant
frequency of 56 kHz in air and spring constant of 0.24 N/m. In the engaged mode, the
frequency dropped to approximately 8 kHz. The AFM scans were performed at a rate
ranging from 1.4 to 2.6 Hz, a scan size on the order of a few microns, a Z-range of 50 nm
and a Z-range phase of 10 degrees.

Vibrating sample magnetometry
A room-temperature Lakeshore vibrating sample magnetometer (VSM) with a 3-T
magnetic field sweep was used to measure key magnetic properties of nanoparticles
under study including the magnetization saturation and the magnetic coercivity. A
cryogenic VSM Quantum Design PPMS with a 9-T superconducting magnet was used to
measure M-H temperatures in a wide temperature range, from 4 K to over 300 K.
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Transmission electron microscopy
Phillips CM-200 200 kV Transmission Electron Microscope (TEM) with Energy
Dispersive Spectroscopy (EDS) option was used to obtain TEM images and EDS
profiles.
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CHAPTER IV: DELIVERING PEPTIDES TO GLIOBLASTOMA CELLS BY WAY
OF MAGNETOELECTRIC NANOPARTICLES
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Introduction
Glioblastoma multiforme (GBM) is the most frequent malignant primary brain tumor
representing 32% of all brain tumor cases in adults, and 81% of malignant tumors.
Despite multidisciplinary treatment approaches, including surgical resection and
radiotherapy, GBM has a low prognosis with an average survival period of 15 – 18
months (124-126). A major challenge in the treatment of GBM is delivering the
therapeutic drug across the blood-brain barrier (BBB), a network of specialized brain
endothelial cells with intercapillary distances of ~40µm that tightly regulate ionic
composition, prevent macromolecules and unwanted cells from entering the brain to
protect the central nervous system (CNS) from neurotoxins (127-131). The use of
targeted drug delivery with relatively small magnetic particles (<40-nm) has been
suggested as an efficient way to cross BBB, target cancerous cells, and permit an ondemand release of anti-tumor drugs.
Due to the multiferroic physics of MENs, these nanoparticles offer properties that
cannot be achieved by any other nanoparticles, such as the traditional ferromagnetic nonsuperparamagnetic and superparamagnetic iron oxide nanoparticles (SPIONs). MENs
display an intrinsic non-zero magnetoelectric (ME) effect which is an important trait that
ultimately defines drug carrier properties, mainly; (i) the strength of the bond between the
nanoparticle and the loaded drug, and (ii) the local electric field on the MENs’ surface
that contributes to the cellular membrane penetration, these two properties can be
controlled via application of special sequences of d.c. and a.c. magnetic fields.
MIA690 peptide is a recently discovered growth-hormone and release-hormones
(GHRH) antagonist with promising anticancer effects on GBM cells. Hypothalamic
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growth hormone-releasing hormone (GHRH) regulates the synthesis and release of GH in
the pituitary gland. GHRH and its mRNS are expressed in many human cancers,
suggesting that it may act as a tumor growth factor (132, 133). GHRH antagonists have
been studied as a treatment for this tumor type. However, major challenges in treatment
with GHRH antagonist exist include prolonging of the drug half-life and delivering the
drug across the BBB for localized drug release specifically to GBM cells.
It is well-established that the MIA class of GHRH antagonists exhibits high binding
affinities to GHRH receptors and display anticancer properties. MIA690 is a synthetic
peptide that has been recently developed as a promising treatment for glioblastomas.
The unprecedented properties of MENs combined with the effectiveness of MIA
GHRH forecast a promising therapy treatment for GBM. However, open questions
include whether MIA690 peptides can bind to MENs with sufficient affinity to penetrate
human glioblastoma cell membrane and then released on-demand. Furthermore, it is
important to note that MENs penetrate the BBB and specifically enter cancer cells while
avoiding cellular uptake from non-malignant cells in the brain vasculature when exposed
to equivalent d.c. fields.
The primary objective is to present an in vitro study in which (i) MIA690 is
efficiently bound to MENs as a drug delivery carrier, (ii) MIA690 loaded MENs
penetrate human glioblastoma cell membranes by application of a relatively weak d.c.
magnetic field, and (iii) the release of the MIA690 antagonist drug in the cell cytoplasm
through the application of an a.c. magnetic field. Demonstrating these specific aims will
revolutionize nanomedicine and provide a solution to overcome the challenges in the
treatment of GBM.
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Results
Characterization of MENs
AFM and TEM-EDS images of 30-nm MENs are shown in Fig. 4.1a,b, respectively. Xray diffraction (XRD) confirmed the tetragonal crystal structure of BaTiO3 shell (space
group P4mm, a = 3.9940 Å c = 4.0380 Å) and the cubic structure of CoFe2O4 cores.
Vibrating sample magnetometry (VSM) results showed that the saturation magnetization
and coercivity of MENs were approximately 1 emu/g and 310-Oe, respectively, and those
of the CoFe2O4 core particles were approximately 40 emu/g and 90-Oe, respectively,
shown in Fig.4.2.

Figure 4.1 Atomic Force Microscopy and Transmission Electron Microscopy image of
Magnetoelectric nanoparticles. (A) AFM images taken at 5.0 µm X 5.0 µm and a vertical
scale of 0.10 µm. (B) TEM image of MENs, arrows indicate isolated magnetoelectric
nanoparticles within the aggregated structure particle agglomeration occurs during
preparation (drying) of colloidal stable fluids for TEM investigation. (C) EDS mapping
of elemental composition of MENs. Scale bar is 50 nm.
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Figure 4.2. VSM measurements of MENs coreshell and core structures. M-H hysteresis
loops showing the saturation magnetization and coercivity of MENs were approximately
1 emu/g and 310 Oe, respectively. The insert shows the M-H hystereis loops for the
CoFe2O4 core with a greater saturation magnetization and lower coercivity of
approximately 40 emu/g and 90 Oe, respectively.
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GHRH antagonist MIA690 loaded MENs
To ensure adequate biocompatibility, MENs were coated with glycerol; monooleate
(GMO) before conjugation with MIA690, as described in detail in section Methods.
Using GMO ensured that the field necessary for inducing local electroporation of the cell
membrane and consequent release of the peptide into the cell were within adequate
ranges of magnitude (~<100-Oe) and frequencies (~<1000-Hz). The effectiveness of the
conjugation procedure was tested by creating a standard calibration curve from MIA690
stock solution and by measuring the absorbance maxima of the unbound MIA690.
Percent retained of MIA690-GMO-MENs was calculated using the following equation:
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Results indicated that the functionalized GMO-MENs carriers could retain 72.7% of
MIA690 Fig.4.3.

Figure 4.3. Bioconjugation of MIA690 to GMO-MENs. GMO-MENs can effectively
bind MIA690 at room temperature in PBS solution (pH=7.4).
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Field controlled uptake and on-demand release of MIA690 in U-87MG cells

Several controls and experimental U-87MG cell treatments were utilized to compare the
effect of drug delivery treatment vs. treatment alone (outlined in Method section).
Briefly, cell were treated with (i) PBS vehicle solution; (ii) GMO-MENs vehicle solution;
(iii) MIA690 treatment only; and (iv) GMO-MENs + MIA690 treatment. Each treatment
group was exposed to magnetic fields categorized as “before on-demand release” (d.c.
fields only) or “after on-demand release” (d.c. field, then a.c. field). Duration of magnetic
field exposure was introduced as a third variable to investigate the effect of time on
intracellular drug release (i.e. 2 hours or 12 hours d.c. exposure + 30 min or 2 hours a.c.
exposure). Data was collected at two separate time points (24 hours and 48 hours after
field application) in replicates of at least n=2. Free MIA690 drug in cell lysate was
measured spectrophometrically against a standard calibration curve of MIA690, and the
results were normalized to the protein content in the cell lysate. The absorbance maxima
of MIA690 in cell lysate was 220-nm, which corresponds to the peptide bonds of
MIA690. The Bradford method to detect proteins normalized drug content in lysate to the
relative number of cells in the sample. The Bradford method detects proteins > 300kDa,
which is beyond the limit of MIA690 (MW=3934 Da). To ensure the peptide MIA690
did not significantly contribute to absorbances obtained by the Bradford method, we
measured the maximum concentration of the peptide treatment (1-µM MIA690) using the
Bradford method. Results indicated absorbances of MIA690 were negligible compared to
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the average protein content of cells indicating that MIA690 does not contribute to protein
values Fig. 4.4. Results from intracellular measurements suggest that MIA690 uptake
increased significantly only in cells treated with Mia690 loaded MENs and exposed to
100-Oe for 12 hours in lysate collected 24 hours post treatment. Drug uptake increased
by a factor of 6.9 for MIA690 carried by field-controlled MENs exposed to an extended
d.c. field compared to the drug administered alone, and this factor increased to 11 with
on-demand release using a.c. magnetic field for 2 hours. Fig.4.5a. Notably, cells exposed
to brief d.c. fields (~2 hours) did not significantly increase intracellular release of
MIA690 regardless of a.c. field exposure. In cell lysate measurements 48 hours post
treatment, uptake of MIA690 is increased by a factor of at least 4.6 in U-87MG cells
treated with MIA690 loaded MENs and exposed to 100-Oe for 12 hours with and without
the application of an a.c. field Fig 4.5b; however, these results did not reach statistical
significance.

Figure 4.4. Bradford assay results are not affected by MIA690 peptide indicating that
MIA690 peptide does not contribute to average cell protein content.
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Figure 4.5. GHRH antagonist (MIA690) uptake relative to protein content in cell lysate across
treatment groups. (A) Intracellular levels of MIA690 increased significantly (p<0.01) when U87MG cells were treated with MIA690 bound to GMO-MENs and exposed to a prolong d.c. magetic
field (12 hours) compared to MIA690 treatment alone. Release of MIA690 was further increased
with the application of an a.c. field (p<0.05). Intracellular levels of MIA690 did not differ
significantly when drug was free in media or delivered bound to MENs carrier and not exposed to a
magnetic field or a short duration of magnetic field (~2 hours d.c. field). (B) Drug uptake 48 hours
post- treatment did not show significant differences between groups when measured in cell lysate.
Reported values were normalized relative to control treatments of PBS or PBS+MENs only vehicle
solutions

U-87MG cell viability decreased with MIA690-loaded MENs delivery

A key mechanism of action of the GHRH antagonist MIA690 is to inhibit cancer cell
proliferation (134-138). We investigated the effect on cell inhibition when MIA690 was
delivered to U-87MG cells using field controlled MENs as drug delivery vehicles.
Vehicles controls included PBS only and GMO-MENs only. Viability was measured by
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taking an aliquot from the sample of cells and staining it with trypan blue, a dye that will
distinguish between viable cells and dead cells using hemacytometer in triplicate. Results
show a decrease in cell viability at 24 hours post treatment when MIA690 was delivered
through GMO-MENs and exposed to a field of 100-Oe d.c. for 12 hours and 50-Hz for 2
hours, however the results were not statistically significant compared to traditional
treatment of MIA690 alone (-7.8%, p=0.285). Cell death was enhanced at 48 hours in cell
treatment with MIA690 bound to GMO-MENs and exposed to 100-Oe for 12 hours then
50-Hz for 2 hours compared to MIA690 treatment alone (-18.3%, p=0.03), Fig. 4.6a. The
relationship between % intracellular MIA690 levels and % cell inhibition is plotted in
Fig. 4.6b. There is a significant relationship between intracellular MIA690 levels and %
cell inhibition indicating that increased intracellular MIA690 is significantly associated
with cell growth inhibition (R2 = 0.43, p=0.001).
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Figure 4.6. Intracellular MIA690 release affects relative cell viability across treatment
groups. (A) Significant decrease in cell viability occurred in cells treated with MIA690GMO-MENs for 12 hours 100 Oe + 50 Hz for 2 hours, compared to MIA treatment alone
(-18.3%, p=0.030). The results are mean ± SEM of three independent measurements. (B)
Intracellular MIA690 is significantly associated with cell growth inhibition in a linear
regression model using data collected at 24 hours and 48 hours post-treatment (R2=0.43,
p=0.001).
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The effect of a low a.c. magnetic field on heat dissipation and cell viability
The expected, relatively low magnetic fields used to couple with MENs did not produce
significant heating across treatment group. The a.c. frequency used in this study is in the
near-d.c. range and thus barely induces hysteresis-triggered thermal dissipation. FIIR-i3
infrared (IR) imaging measured heat dissipation at each stage of field exposure to
magnetic field. There were no significant differences between flask temperatures of
control and GMO-MENs treated flasks, regardless of the length of time or magnetic field
exposure (d.c. or a.c.). Cell viability did not differ significantly between GMO-MENs
treated cells with or without exposure to a.c. magnetic fields Fig. 4.7.
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Figure 4.7. The effect of a.c.magnetic fields on heat dissipation of MENs and cell
viability. (A)Heatimages displaying surface temperatures of cell cultures treated with
MENs compared to controls. No significant differences in temperatures were observed
between groups. (B) Relative cell viability between groups exposed to varying durations
of a.c. magnetic fields. Exposure to a.c. magnetic fields had no significant effects on cell
viability.

67

MENs specifically penetrate U-87MG cells
The intracellular uptake of MENs was imaged across treatment groups using EDS-SEM.
The EDS-SEM provides an atomic-level elemental composition of the material and
identifies atomic signatures of GMO-MENs. Because MENs are composed of a CoFe2O4
core with a BaTiO3 shell, the atomic signatures of Ba and Ti indicate the presence of
MENs in the cell lysate. The samples showing the highest traces of Ba and Ti were
exposed to 100-Oe for 12 hours compared to controls, indicating that MENs loaded with
MIA690 effectively penetrate U-87MG cells with the application of a d.c. magnetic field
Fig. 4.8a. ICP-MS was performed to quantify amounts of Ba and Ti in the cell lysate.
Results showed that following d.c. treatment for 12 hours, the average Ba concentration
was 18.7±2.7 µg/L, and Ti concentration was 98.6±2.5 µg/L confirming the presence of
MENs particles in cell lysate.
Specificity of MENs to target cancer cells was investigated by treating healthy
cells (HBMECs) and cancer cells (U-87MGs) with fluorescently labeled MENs. FITCloaded MENs were redispersed in cell media and exposed to a d.c. magnetic field (~100Oe) hypothesized to produce electroporation in cancer cells while sparing healthy cells.
Results of confocal fluorescent images indicate that FITC-MENs are highly localized in
the cytoplasm of the malignant U-87MG cells and are not associated with the nonmalignant HMBEC cells Fig. 4.8b.
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Figure 4.8. MENs uptake in malignant glioblastoma cells using a relatively weak d.c.
magnetic field. (A) EDS-SEM images of signature trace elements Ti and Ba in the cell
lysate of U-87MG cells treated with MIA-GMO-MENs exposed to 100 Oe d.c. magnetic
field. The arrows indicate where the MENs are most concentrated in the sample. (B)
Confocal images showing the specific interaction of MENs with malignant glioblastoma
cells. FITC-MENs are specifically associated with U-87MG cells. Uptake is not evident in
non-malignant HBMECs.
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MENs cross blood-brain barrier in vivo
EDS-SEM imaging detected elemental signature traces of MENs coreshell in the brain
slices of mice. Results show the presence of Ba and Ti signature elements of the MENs
coreshell in the parenchyma of the mouse brain shown in Fig. 4.9.

Figure 4.9. EDS-SEM images of signature trace elements Ti and Ba in the parenchyma
brain tissue in mice injected IV with MENs. (A) High-resolution image of MENs fixed in
the brain parenchyma of a mouse. The green and blue images show the concentrated
regions of Ba and Ti, respectively. (B) The red arrows show the blood vessels of the
BBB, the orange target indicates the location of EDS analysis, and the orange arrows on
corresponding EDS spectrum indicate detection of Ba and Ti. The signature trace
elements of MENs coreshell were detected outside of the brain vasculature, indicating
MENs are able to cross the BBB in vivo.
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Discussion
Current treatment for malignant glioblastoma including surgery, radiotherapy, and
chemotherapy are being applied with limited success (139-142). GHRH antagonists are
being developed to improve the outcome of the treatment to improve the overall survival
rate of GMB patients. The effects of GHRH antagonist in experimental treatment have
demonstrated beneficial models that include the suppression of the pituitary hepatic IGF
axis, and secondly, direct inhibition of the autocrine/paracrine activity of GHRH.
However, delivery of GHRH antagonist to target sites in the brain is limited by their short
half-life in circulation and relatively inefficient delivery to glioblastoma across the BBB.
Therefore, an approach for tightly binding GHRH antagonist to a carrier particle to avoid
degradation, directing the drug-loaded conjugate across the BBB, and controlling the
release of the drug will provide improved treatment outcomes.

The use of MENs as drug delivery vehicles for cancer therapies is being studied both in
vitro and in vivo (143, 144). MENs as drug carriers can be loaded with a GHRH
antagonist, administrated intravenously, and then navigated across BBB via application
of a d.c. magnetic field gradient. In general, MRI or MPI can be used as an imaging
modality to provide an image guided delivery of MENs directly to tumor sites using d.c.
magnetic field gradient, recently, it has been shown that MENs can be localized to tumor
sites due to a physical mechanism which acts independently of the enhanced permeability
and retention (EPR) effect (143). According to this mechanism, drug-loaded MENs are
attracted to the tumor cells due to their more conductive membrane surface and the
resulting stronger Coulomb force compared to that of the normal cells. When in close
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proximity to the tumor cell membrane, MENs induce local electroporation to the cell
membrane, the effect known as the nanoelectroporation, which further pulls the
nanoparticles inside the cells. The specificity exists because the nanoelectroporation
threshold field for the malignant cell is significantly lower than that for the surrounding
non-malignant cells. Upon entering into the cytosol, an on-demand release of the peptide
into the intracellular microenvironment is achieved by application of an a.c. magnetic
field. The physical mechanism of the release relies on the strong a.c. field dependence of
the bond affinity between the nanoparticle and the drug due to the ME effect (66-69).

The present data support the concept that MENs can effectively bind to GHRH antagonist
MIA690 at physiological pH and can deliver MIA690 more efficiently to malignant
glioblastoma cells than the free drug alone in vitro. Furthermore, the data confirm that
MENs exposed to magnetic field increases specificity to malignant glioblastoma cells
while sparing non-malignant cells and can cross the BBB in vivo, which may lead to
localization of MIA690 to glioblastoma cells in the brain.

Conjugation of MIA690 to GMO-MENs using an EDC-linker resulted in 72% of
MIA690 loaded onto the GMO-MENs carrier at physiological pH. This result is
consistent with the binding capacity of chemotherapeutic drugs to MENs previously
reported. An important challenge in the administration of GHRH antagonist is their short
half-life. Various nanocarriers are emerging as delivery systems to improve half-life of
therapeutic peptides. The binding force between MIA690 and MENs at physiological pH
indicates that GHRH antagonist may avoid early degradation when loaded onto MENs
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carriers in order to reach targeted sites. It is worth noting that MENs-based delivery and
release across the BBB is independent of the biochemical microenvironment; in contrast,
it is mostly determined by externally d.c. and a.c. magnetic fields.

Conclusion
Overall, this study reports major improvements in therapy of human glioblastoma with a
GHRH antagonist. Taking advantage of the unique properties of magnetoelectric
nanoparticle. These results suggest that (1) GMO-MENs effectively bind MIA690, (2)
provide controlled intracellular drug delivery, (3) specifically target human glioblastoma
cells, and (4) penetrate the blood-brain barrier. As a final remark, it is worth mentioning
that, in general, this nanotechology could be applied to treat not only brain tumors but
also neurodegenerative diseases such as Alzheimer’s Disease and Parkinson’s Disease.

Materials and Procedures
Reagents and chemicals
Sigma- Aldrich (MO, USA). Cellular experiments in vitro utilized the human
glioblastoma cell line U- 87MG and human brain microvascular endothelial cells
(HBMECs) obtained from the commercial provider American Tissue Culture Collection
(ATCC, VA, USA). Modified Eagle’s medium (MEM), Dulbecco’s Modified Eagle’s
medium (DMEM), fetal bovine serum (FBS) from Gibco (NY, USA), and penicillinstreptomycin (penstrep) obtained from Science-Cell, Inc. (CA, USA). For fluorescence
experiments, fluorescein isothiocyanate (FITC) amine reactive dye and 4’,6-Diamidino2-Phenylindole (DAPI) were purchased from Thermo Fisher Scientific (MA, USA). All
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reagents met or exceeded ACS standards for procedures requiring stringent quality
specifications.

Synthesis and characterization of MENs
Magnetoelectric nanoparticle (MENs) were synthesized in our laboratory by conventional
methods.52 In the first step, CoFe2O4 core particles were prepared by the standard
hydrothermal method. Thus, 0.58 g of Co(NO3)2 . 6H2O and 0.16 g of Fe(NO3)3 .
9H2O were dissolved in 150 mL of aqueous solution. An aqueous mixture of
polyvinylpyrrolidone (0.2 g) and sodium borohydride (0.9 g) was then added and stirred
at 70°C for 12 hours. The precursor solution of BaTiO3 was prepared by mixing 174 mg
of BaCo3 and 5 g citric acid with 240 uL titanium isopropoxide in ethanolic solution.
CoFe2O4 cores were added to the BaTiO3 precursor solution and sonicated until fully
dispersed (~2 hours). The mixture was heated at 90°C with continuous stirring overnight
to form a milky opaque gel. The gel was placed in the KSL-1100x high temperature
muffle furnace from MTI Corporation (CA, USA) to calcine at 600°C for 5 hours with
controlled ramping temperatures to obtain coreshell of MENs of ~30 nm diameter. Size
distribution of MENs was confirmed by atomic force microscope (AFM) imaging to
assess grain height using the Bruker Nanoscope IIIa Multimode (MA, USA) and TEM
imaging using the FEI Talos F200X instrument (Oregon, USA).

Conjugation of GHRH antagonist peptide MIA690 to MENs
Five grams of 30 nm CoFe2O4-BaTiO3 coreshell MENs particles were resuspended in 1
mL sterile phosphate buffered saline (PBS, pH 7.4) and sonicated for 1 minute. To
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improve the biocompatibility of MENs, 0.1 mL of glycerol monooleate (GMO) was
mixed with the MENs coreshell in and rotated for 1 hour. GMO-MENs were washed
thrice with PBS, then N-(3- Dimethylaminopropyl)-N’-ethyl-carbodiimide hydrochloride
(EDC) at 1 mg/ml concentration was added to the solution and incubated for 1 hour by
slow mechanical stirring. The GHRH antagonist, synthesized by R-Z. Cai and A.V.
Schally using solid phase methods was conjugated to the functionalized GMO-MENs to
produce a stock solution of MIA690-GMO-MENs that could be mixed with cell culture
media to a final peptide concentration of 1 µM MIA690. The treatment with GHRH
antagonists at the concentration of 1 µM has previously reduced cell viability and
generated antitumor effects in GBM cell culture.25 To determine the binding efficacy of
MIA690 to GMO-MENs, stock solution was centrifuged at 4,000 rpm to separate
unbound peptide from the pellet. The supernatant was resuspended in PBS and
absorbance was measured spectrophotometrically and concentrations were plotted against
a calibration curve of known MIA690 concentration.

Cell Culture
U-87MG cells were grown in T-25 flasks seeded with 0.5 X 106 cells/flask and cultured
with MEM media supplemented with 5% FBS and 1% penstrep. Human brain
microvascular endothelial cells (HBMECs) were grown in DMEM media supplemented
with 10% FBS and 1% penstrep. Cell cultures were incubated at 37°C with 5.0% CO2 in
a humidified atmosphere. Media was replaced every 2-3 days until cells reached
confluency. Confluent cells were detached with 0.25% trypsin/EDTA solution and
reseeded. Drug uptake experiments were performed at 80% confluency, and data
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collected at 24 hours and 48 hours post-treatment with MIA690-loaded MENs or
MIA690 alone. Samples were read in duplicate and triplicate when necessary to obtain
acceptable % CV values.

In vitro treatment
Cells were treated with MIA690 alone or MIA690-GMO-MENs in fresh media at a
concentration of 1 µM of MIA690. Equivalent volumes of the vehicle solutions (“naked”
GMO-MENs, or PBS) were added to the media as controls. Each treatment group
(MIA690, MIA690-GMO- MENs, GMO-MENs, PBS) was exposed to several magnetic
field conditions to test the effect of a d.c. magnetic field gradient (reported in Oe) to
induce penetration into U-87MG cells. Subsequently, selected treatment groups were
exposed to an a.c. magnetic field (reported in Hz) to examine the on-demand release of
MIA690 from the nanoparticle. The duration of exposure to a magnetic field was
controlled to determine the optimal exposure time that would improve MIA690 uptake.
We chose a combination of treatment groups based on prior MENs data14; U- 87MG
cells treated with MIA-GMO-MENs were exposed to the following magnetic fields in
sequence (a) no field, 0 Oe + 0 Hz; (b) 2 hours 100 Oe + 0 Hz (c) 2 hours 100 Oe + 50
Hz 30 min; (d) 2 hours 100 Oe + 50 Hz 2 h; (e) 12 hours 100 Oe + 50 Hz 30 min; (f) 12
hours 100 Oe + 50 Hz 2 hours

Intracellular release of GHRH antagonist MIA690 from MENs in GBM
To determine the amount of intracellular uptake and release of MIA690, the amount of
free drug in the cell lysate was quantified spectrophometrically. It is accepted that cell
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lysate components represent the intracellular content of cells.53 Following the treatment
and exposure to magnetic fields, U-87MG cells were allowed to incubate further for 24
hours or 48 hours. Then media was discarded, cells were washed with PBS and detached
with 0.25% trypsin/EDTA solution. Cells were collected in a conical tube, pelleted by
centrifugation and washed thrice with ice cold PBS. Cells were resuspended in 1 mL
DMSO and sonicated briefly to induce cell lysis. After 1 hour of incubation at 37°C, the
solution was centrifuged at 10,000 RPM for 5 minutes to pellet cellular debris and MENs.
The supernatant containing the cell lysate was collected to measure the intracellular
concentration of MIA690.

Quantification of MIA690 uptake in cell lysate
An aliquot (20 µL) of cell lysate from each treatment group was diluted in buffer and
measured spectrophometrically on scan mode to capture peak signatures of the peptide. A
standard curve was generated by resuspending known concentrations of MIA690 and
creating serial dilutions. Peak absorbance of MIA690 was captured at the maximum
wavelength of 220 nm. MIA690 uptake was normalized to the protein content of cells
lysate, which is representative of the number of cells in culture. Protein content was
determined immediately after collection to avoid protein degradation with the Bradford
method using Bio-Rad Protein Assay Kit at an absorbance of 595 nm according to BioRad protocol (CA, USA). Final results were reported as % MIA690 per ug protein.
Spectrophometric

measurements

were

performed

spectrophotometer (CA, USA).
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Imaging intracellular uptake and specificity of MENs in U-87MG cells
Cell lysate from each treatment group 24 hours after treatment was collected for imaging
with electron-dispersive spectroscopy (EDS) mode of scanning electron microscopy
(SEM). EDS- SEM detects signature traces of Ba and Ti that is unique to MENs outer
shell. The presence of Ba and Ti in cell lysate indicates efficient nanoelectroporation of
U-87MG cells. One drop of lysate (~10 µL) diluted in TE buffer was dried on a precleaned Si wafer and placed on copper tape mounting for imaging with a JEOL- JIB 4500
multibeam system (FIB/SEM). The Thermo- scientific Noran system 7 performed EDS
analysis. Intracellular uptake of GMO-MENs was observed by comparing the density of
Ba and Ti signal in each image. ICP-MS confirmed the presence of Ba and Ti in the cell
lysate. For specificity data of MENs, malignant U-87MG cells and non-malignant
HBMECs were cultured as previously described and treated with FITC-loaded MENs
(FITC MENs) and DAPI for nuclear staining. U-87MG cells and HBMECs were exposed
to a magnetic field gradient of 100 Oe and intracellular uptake of MENs was quantified
using a confocal fluorescent microscope Olympus Fluoview FS1200 (PA, USA).

Cell viability and magnetic nanoparticles hyperthermic effects
In vitro cell viability of U-87MG cells after treatment with MIA690 or MIA690-GMOMENs and magnetic field exposure was determined using the trypan blue protocol.54
Experimental conditions were identical to those of the treatment groups described
previously. Reported results are relative to the control group treated with a PBS vehicle
solution.
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The magnetic fields used to induce nanoelectroporation may cause heat dissipation
known to produce hyperthermic effects resulting in cell death. Infrared (IR) imaging
captured by the FlIR- i3 camera (OR, USA) measured heat dissipation at each stage of
treatment to ensure that cell culture temperatures remained within normal ranges.
Temperatures were captured at the maximal magnetic field exposures.

The penetration of the blood-brain barrier by MENs in vivo
Immunocompromised mice (Taconic, Inc., NY, USA) were maintained in pathogen-free
conditions in the institutional animal care facility at Florida International University
(FIU). Mice were injected IV into the tail vein with 200 ug/mL GMO-MENs. Following
application of magnetic fields, mice were euthanized be means of CO2 inhalation,
immediately after which tissues were excised and stored in 10% formalin solution
overnight 4°C. The tissues were cleaned under a stereomicroscope and a small piece of
the brain was sectioned and washed with PBS to remove excess fixative. Brain tissue was
carefully dried and transferred to a plastic mold containing OCT. The tissue was frozen
by immersing the mold in a bath of 2- methlybutane/liquid nitrogen, then transferred to a
-80°C freezer overnight before being cut into 10 µm sections with a Leica CM3050
Cryostat (IL, USA). Finally, tissues slices were mounted on VWR Superfrost Plus
microscope slides and dried on a slide warmer at 37°C for 1-2 hours. Slides were then
ready for EDS-SEM analysis to detect signature peaks of the elemental composition of
MENs core-shell (Ba and Ti). All methods used in the study were carried out in
accordance with the approved guidelines of the institutional animal care and use
committee (IACUC) at FIU.
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Vibrating sample magnetometry
A room-temperature Lakeshore VSM system with a 3-T magnetic field sweep was used
to measure key magnetic properties of nanoparticles under study including the
magnetization saturation and the magnetic coercivity. The vibration was induced at a 60Hz frequency. The sensitivity of the system is on the order of 1 µemu. The system was
calibrated by measuring the saturation magnetization of iron oxide and permalloy thin
films.

X-ray diffraction measurements
XRD measurements were conducted using diffractometer BRUKER D5000 with the
following specifications: X-Ray tube: Kalfa C, KBeta filter: Ni (12 micron thickness);
scan type: locked coupled; 2tetha: 20-80 degress; increment: 0.1 degrees; scan speed: 6
sec/step current: 35mA; Voltage: 40 kV; aperture diagram path: 1mm

Statistical analysis
Results are presented as means ± S.D. or percentages. Student’s t-test and one-way
ANOVA with posthoc analyses were conducted to assess significant differences between
treatment groups. All data was collected in replicated of at least n=2 and data were
reevaluated when CV values were greater than 10%. Linear regression models were used
to assess relationships between variables of interest. Statistical analysis was performed
using IBM SPSS software (IL, USA). P-values < 0.05 were considered statistically
significant
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FUTURE WORK
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The overall objective of the dissertation was to implement and study the underline
physics of a novel nanotechnology capable of exploiting the electric properties of the
cellular microenvironment. To summarize, via application of an external magnetic field
we are able to control the magnetoelectric effect of our multiferroic nanoparticles due to
its’ strongly coupled magnetostrictive and piezoelectric properties.

In chapter II we explored the differences between magnetoelectric nanoparticle (MENs)
and other magnetic nanoparticles (MNPs). To clearly differentiate between the two type
of nanoparticles, we explained how like MNPs, MENs have a non-zero magnetic moment
and therefore can be transported throughout the circulatory system via application of an
external magnetic field gradient. However, unlike MNPs, MENs’ magnetoelectric effect
provides a unique way to control an intrinsic electric field that underlies the chemical
bond between the nanoparticles and the loaded drug as well as the interaction between the
drug-loaded nanoparticle and the cellular microenvironment. The targeting mechanism
occurs when in close proximity to the cellular membrane; the electric field on the surface
of the nanoparticle induces a dielectric breakdown affecting the membrane of cancer cells
but not that of normal cells. When MENs enter the cytoplasm of the cancer cell,
application of an a.c. magnetic field breaks the bond between the nanoparticle and the
therapeutic drug, ultimately eradicating the cancer cells while completely avoiding
surrounding normal cells.
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In chapter III the application of MENs as nuclear magnetic resonance (NMR) nanoprobes
for rapid cancer diagnostic was explored. The intrinsically coupled ferromagnetic and
ferroelectric phases allowed the nanoparticles to be used as NMR sensitive nanoprobe
detectors of biological cells; based on the knowledge that the cellular membrane is an
electrically charged medium that can be influenced by the electric field associated with
MENs. The study showed that MENs can significantly enhance the electric charge
configuration on the cellular membrane that can serve as a characteristic signature of the
cell, depending on the cell type and prognosis stage. The enhanced electric field from the
nanoparticle-cell interaction was observed in NMR absorption spectra of cells incubated
with MENs, in contrast to conventional MNPs that showed no change in the NMR
absorption spectra.

In chapter IV an in-vitro study was conducted to deliver MIA690 peptides across the
blood brain barrier (BBB) to glioblastoma multiforme (GBM) cancer cells. The targeting
and treatment of glioblastomas is extremely difficult due to the many variety of cancer
cells associated with the tumor. Taking advantage of the properties of MENs described in
chapter 1, we successfully brought MIA690-MENs across the blood brain barrier via an
external magnetic field gradient. After bypassing the BBB, the loaded MIA690 MENs
was able to penetrate and release the peptide drug in the cellular membrane of the human
glioblastoma cells by way of a relatively weak d.c. and a.c. magnetic fields applications,
respectively.
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To conclude, future work consists of studying the dynamics of intracellular transport.
Specifically, to distinguish the transport due to the traditional cascade process and the
charge-associated transport due to the intrinsic intracellular fields. The hypothesis of
these two processes is characterized by very different time scales. We will use
magnetoelectric nanoparticles (MENs) as an enabling tool to study externally, the charges
associated with intracellular transport in different cellular media to understand how cells
form information circuits that detects, process, and respond to signals in its cellular
microenvironment.
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